Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 9-16

  Mathijssen, Ron H J ^a   Van Alphen, Robbert J ^a   De Jonge, Maja J A ^a   Verweij, Jaap ^a   De Bruijn, Peter ^a   Loos, Walter L ^a   Nooter, Kees ^a   Vernillet, Laurent ^b   Stoter, Gerrit ^a   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b SANOFI   (France)

Author keywords

Cisplatin; Irinotecan (CPT 11); Pharmacokinetics; Pling models; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CISPLATIN; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; PRIORITY JOURNAL; REGRESSION ANALYSIS; SOLID TUMOR;

EID: 0033018091     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00002     Document Type: Article

References (22)

1. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
2. Gerrits CJH, de Jonge MJA, Schellens JHM, Stoter G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76: 952-62.
3. De Jonge MJA, Sparreboom A, Verweij J. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat Rev 1998; 24: 205-20.
4. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
5. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy-lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-21.
6. Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995; 34: 13722-8.
7. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 1996; 32A: S18-23.
8. Takimoto CH, Arbuck SG. The camptothecins. In: Chabner BA, Longo DL, eds. Cancer chemotherapy, and biotherapy. Philadelphia: Lippincott-Raven 1996: 463-84.
9. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4(1-piperidino)-1-piperidino] carbo-nyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36.
10. Verweij J, De Jonge MJA, Sparreboom A, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) and cisplatin in patients with solid tumors. Proc Am Ass Clin Oncol 1998; 17: 188a (abstr).
11. De Bruijn P. Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid Chromatography with fluorescence detection. J Chromatogr 1997; 698: 277-85.
12. Sparreboom A, De Jonge MJA, De Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients, Clin Cancer Res 1998; 4: 2747-54.
13. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
14. Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994; 54:6330-3.
15. Van Warmerdam LJC, Ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 1994; 120: 427-33.
16. Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 1995; 36: 463-72.
17. Sasaki Y, Mizuno S, Fujii H, et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995; 86: 117-23.
18. Nakashima H, Lieberman R, Karato A, et al. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring. Ther Drug Monit 1995; 17: 221-9.
19. Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012-9.
20. Canal P, Gay C, Dezeuze A, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996; 14: 2688-95.
21. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
22. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokin 1997; 33: 245-59.